Table 2: Univariate median survival estimates (months) and hazard ratios.

Median Survival Hazard Ratio
N 95% CI Estimate 95% CI P-Value
Age at diagnosis

< 40*

40-59

60-79

80+

242

687

543

123

Incalculable***

248 ± 33.80

122 ± 12.80

58 ± 10.87

Reference

1.69

3.62

9.78

 

1.24-2.34

2.67-5.00

6.59-14.70

 

< 0.001

< 0.001

< 0.001

Race

White*

Black

Asian/Pacific Islanders

Other/Unknown

1229

153

189

24

181 ± 18.98

205 ± 66.57

132 ± 39.85

184 ± 60.41

Reference

0.99

1.28

1.37

 

0.75-1.30

0.99-1.64

0.62-2.63

 

0.999

0.055

0.323

Gender

Female*

Male

952

643

198 ± 22.57

147 ± 21.58

Reference

1.24

 

1.06-1.46

 

0.008

Received Radiation

Yes*

No

Unknown

1116

454

25

173 ± 19.66

188 ± 35.50

Incalculable***

Reference

0.95

0.71

 

0.79-1.13

0.28-1.47

 

0.571

0.515

Surgery

Yes*

No

Unknown

535

62

998

194 ± 24.11

71 ± 12.02

206 ± 72.13

Reference

2.72

1.09

 

2.00-3.65

0.91-1.31

 

< 0.001

0.343

Surgery Type

Gross*

Partial

None

Other/Unknown

383

148

62

1002

194 ± 32.50

197 ± 34.51

71 ± 12.02

181 ± 38.73

Reference

0.92

2.63

1.05

 

0.71-1.20

1.91-3.56

0.86-1.28

 

0.566

< 0.001

0.625

Lymph Node Involvement

Yes*

No

Unknown

392

1194

9

111 22.76

203 22.31

38 2.44

Reference

0.56

2.69

 

0.48-0.66

1.05-5.75

 

< 0.001

0.020

Tumor Size (mms in largest dimension)

< 21*

21-40

> 40

Unknown

599

586

181

229

260 ± 28.53

143 ± 21.06

89 ± 14.45

148 ± 24.74

Reference

1.85

3.29

1.85

 

1.52-2.26

2.54-4.25

1.46-2.36

 

< 0.001

< 0.001

< 0.001

Tumor Site

Major Salivary Glands*

Palate

Unspecified Mouth Parts

Tongue

Mouth Floor

Nasopharynx

Lip

Other

935

266

111

108

43

53

49

30

203 ± 32.92

184 ± 34.73

197 ± 67.11

10.3 ± 29.11

139 ± 63.86

59 ± 19.34

173 ± 51.55

129 ± 157.19

Reference

1.08

0.97

1.81

1.57

3.13

1.13

1.73

 

0.86-1.35

0.69-1.34

1.36-2.40

0.97-2.42

2.16-4.40

0.69-1.76

0.78-3.34

 

0.466

0.936

< 0.001

0.056

< 0.001

0.552

0.116

*Reference group against which other groups' survival experience are compared; **P value for log-rank testing the null hypothesis that the groups' survival experience is same as reference group; ***Median includable as more than 50% survived by end of study.